On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
An email from Ben Lipsky brings new biomarker data — IL-17, IL-12p70, HMGB1, IL-8, CRP — that may be the strongest case yet for splitting "moderate" and "severe" diabetic foot infections in the IDSA and WIfI classification.
Senneville and Lipsky return with a measured rejoinder in Clinical Infectious Diseases (April 2026), arguing that the Lagrand trial shows the absence of evidence of superiority — not definitive equivalence — between ulcer-bed and bone biopsy for guiding antibiotic therapy in diabetic foot osteomyelitis.
Exciting new data from our friend and colleague Ben Lipsky and his team highlights a potential shift in how we approach one of our most stubborn challenges: Staphylococcus aureus (StA) in diabetic foot osteomyelitis (DFO). Current standards of care for DFO are often unsatisfactory. This Phase 2, randomized, double-blind, placebo-controlled trial investigated BX211, a personalized... Continue Reading →
